Lessons from $800-million drug flop may lead to a new genre of anti-cholesterol medicines
Wednesday, February 22, 2012 - 13:00
in Health & Medicine
Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body. A report on how three new versions of medications in the same family as the failed torcetrapib appears in the current edition of Chemical & Engineering News, the newsmagazine of the American Chemical Society, the world's largest scientific society.